Patent · US Active

Quinazoline derivatives as antitumor agents

US11723908B2 · kind B2 · utility

0Cited by

1References

36Claims

0Family size

Assignee

SUZHOU ZANRONG PHARMA LIMITED · CN

Inventors

Ding Zhou · Shanghai, CN
Ziqiang CHENG · Shanghai, CN

Key dates

Filing date	Sep 17, 2019
Grant date	Aug 15, 2023
Priority date	—
Expiry date	Jul 29, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present application relates to novel quinazoline compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.